AstraZeneca PLC (LSE:AZN) is acquiring clinical-stage oncology group Fusion Pharmaceuticals in a $2.4 billion (£1.9 billion) deal. The offer represents a massive 126$2 billion upfront at $21 per share followed by a contingent$3 per share “upon the achievement of a specified regulatory milestone”. Fusion “will complement AstraZeneca's leading oncology portfolio with the addition of the Fusion pipeline of RCs, including their most ...